08:00 , Jan 14, 2013 |  BC Week In Review  |  Company News

Inotek board of directors update

Inotek Pharmaceuticals Corp. , Lexington, Mass.   Business: Ophthalmic, Renal, Autoimmune   Appointed: David King as executive chairman, formerly CEO of BioRexis Pharmaceutical Corp. which Pfizer Inc. acquired  ...
08:00 , Dec 8, 2008 |  BC Week In Review  |  Company News

Diasome board of directors update

Diasome Pharmaceuticals Inc. , Conshohocken, Pa.   Business: Drug delivery, Endocrine   Appointed: David King as chairman, formerly CEO of BioRexis Pharmaceutical Corp.  ...
07:00 , Jun 30, 2008 |  BioCentury  |  Strategy

Biotherapeutic shopping spree

Biotherapeutic shopping spree Company/Institution Year Deal type Products/technologies obtained California Institute for Quantitative Biosciences (QB3) 2008 Research alliance Deal to enable any researcher from UC San Francisco, UC Santa Cruz and/or UC Berkeley to collaborate...
07:00 , Jun 16, 2008 |  BioCentury  |  Finance

Ebb & Flow

Invitrogen needs uplift By Stacy Lawrence Senior Writer Despite the prospect of creating a mammoth provider of reagents and systems via the acquisition of Applied Biosystems (NYSE:ABI), investors in Invitrogen (NASDAQ:IVGN) seemed uncertain about how...
07:00 , May 5, 2008 |  BioCentury  |  Strategy

Change of phase

Since its inception in 2002, Phase Bioscience Inc. has been purifying recombinant proteins and antibodies as a service for others using technologies based on elastin-like polypeptides. Having raised $7.7 million last October and with a...
07:00 , Apr 28, 2008 |  BioCentury  |  Finance

Ebb & Flow

On Friday, investors savaged Isis (NASDAQ:ISIS) and dinged partner Genzyme (NASDAQ:GENZ) on news that NDA submissions for their mipomersen cholesterol-lowering drug would take longer than anticipated. Isis fell $4.81 (29%) to $11.99, while Genzyme dipped...
07:00 , Apr 21, 2008 |  BC Week In Review  |  Company News

Phase Bioscience Inc. management update

Phase Bioscience Inc. , Morrisville, N.C.   Business: Drug delivery, Cancer, Endocrine   Hired: Christopher Prior as CEO and a director, formerly president and CSO of BioRexis Pharmaceuticals Corp. (now part of Pfizer Inc. );...
01:26 , Apr 16, 2008 |  BC Extra  |  Company News

Phase Bioscience names Prior CEO

Phase Bioscience (Morrisville, N.C.) hired Christopher Prior as CEO and a director. Previously, Prior was president and CSO of BioRexis , which was acquired by Pfizer (NYSE:PFE) last year. He replaces M. Nixon Ellis, who...
07:00 , Mar 24, 2008 |  BC Week In Review  |  Company News

Xencor board of directors update

Xencor Inc. , Monrovia, Calif.   Business: Autoimmune, Cancer, Computational chemistry/biology   Appointed: David King as chairman, co-founder and former CEO of BioRexis Pharmaceuticals Corp., which was acquired by Pfizer Inc.  ...
01:24 , Mar 20, 2008 |  BC Extra  |  Company News

Xencor names King chairman

Autoimmune and cancer company Xencor (Monrovia, Calif.) appointed David King chairman. Previously, he was CEO of BioRexis , which was acquired by Pfizer (NYSE:PFE) last year....